Oral activity of a methylenecyclopropane analog, cyclopropavir, in animal models for cytomegalovirus infections

被引:57
作者
Kern, ER
Bidanset, DJ
Hartline, CB
Yan, ZH
Zemlicka, J
Quenelle, DC
机构
[1] Univ Alabama, Sch Med, Dept Pediat, Div Infect Dis, Birmingham, AL 35233 USA
[2] Wayne State Univ, Sch Med, Barbara Ann Karmanos Canc Inst, Detroit, MI USA
关键词
D O I
10.1128/AAC.48.12.4745-4753.2004
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
We reported previously that purine 2-(hydroxymethyl)methylenecyclopropane analogs have good activity against cytomegalovirus infection. A second-generation analog, (Z)-9-{[2,2-bis-(hydroxymethyl)cyclopropylidene] methyl}guanine (ZSM-I-62, cyclopropavir [CPV]), has particularly good activity against murine and human cytomegaloviruses (MCMV and HCMV) in vitro. To determine the oral activity of this compound in vivo, BALB/c or severe combined immunodeficient (SCID) mice infected with MCMV and two models using SCID mice implanted with human fetal tissue and subsequently infected with HCMV were used. In MCMV-infected normal mice, CPV at 10 mg/kg of body weight was highly effective in preventing mortality when administered at 24, 48, or 72 h post-viral inoculation and reduced titers of virus in tissues of SCID mice by 2 to 5 log,,. In one HCMV model, human fetal retinal tissue was implanted into the anterior chamber of the mouse eye and inoculated with the Toledo strain of HCMV, and in the second, human fetal thymus and liver tissues were implanted under the kidney capsule of mice and then inoculated with HCMV. In general, replication of HCW in both types of implant tissue increased from 7 through 21 to 28 days and then gradually decreased to undetectable levels by 8 weeks postinfection. Oral treatment with 45 or 15 mg of CPV/kg initiated 24 h after infection was highly effective in reducing replication to undetectable levels in both models and was generally more effective than ganciclovir. These data indicate that the methyllenecyclopropane analog, CPV, was highly efficacious in these four animal models and should be evaluated for use in HCW infections in humans.
引用
收藏
页码:4745 / 4753
页数:9
相关论文
共 50 条
[1]   NOVEL METHOD FOR EVALUATING ANTIVIRAL DRUGS AGAINST HUMAN CYTOMEGALOVIRUS IN MICE [J].
ALLEN, LB ;
LI, SX ;
ARNETT, G ;
TOYER, B ;
SHANNON, WM ;
HOLLINGSHEAD, MG .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (01) :206-208
[2]   Z-isomers of 2-hydroxymethylcyclopropylidenemethyl adenine (synadenol) and guanine (synguanol) are active against ganciclovir- and foscarnet-resistant human cytornegalovirus UL97 mutants [J].
Baldanti, F ;
Sarasini, A ;
Drach, JC ;
Zemlicka, J ;
Gerna, G .
ANTIVIRAL RESEARCH, 2002, 56 (03) :273-278
[3]   A RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF ORAL ACYCLOVIR FOR THE PREVENTION OF CYTOMEGALO-VIRUS DISEASE IN RECIPIENTS OF RENAL-ALLOGRAFTS [J].
BALFOUR, HH ;
CHACE, BA ;
STAPLETON, JT ;
SIMMONS, RL ;
FRYD, DS .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 320 (21) :1381-1387
[4]   Oral activity of ether lipid ester prodrugs of cidofovir against experimental human cytomegalovirus infection [J].
Bidanset, DJ ;
Beadle, JR ;
Wan, WB ;
Hostetler, KY ;
Kern, ER .
JOURNAL OF INFECTIOUS DISEASES, 2004, 190 (03) :499-503
[5]  
Bidanset DJ, 2002, ANTIVIR RES, V53, pA61
[6]   Replication of human cytomegalovirus in severe combined immunodeficient mice implanted with human retinal tissue [J].
Bidanset, DJ ;
Rybak, RJ ;
Hartline, CB ;
Kern, ER .
JOURNAL OF INFECTIOUS DISEASES, 2001, 184 (02) :192-195
[7]  
BIDANSET DJ, 1999, HDB ANIMAL MODELS IN, P957
[8]   Rate of emergence of cytomegalovirus (CMV) mutations in leukocytes of patients with acquired immunodeficiency syndrome who are receiving valganciclovir as induction and maintenance therapy for CMV retinitis [J].
Boivin, G ;
Gilbert, C ;
Gaudreau, A ;
Greenfield, I ;
Sudlow, R ;
Roberts, NA .
JOURNAL OF INFECTIOUS DISEASES, 2001, 184 (12) :1598-1602
[9]   Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus [J].
Chou, SW ;
Lurain, NS ;
Thompson, KD ;
Miner, RC ;
Drew, WL .
JOURNAL OF INFECTIOUS DISEASES, 2003, 188 (01) :32-39
[10]  
Chulay J, 1999, ADV EXP MED BIOL, V458, P129